PRAMIPEXOLE DIHYDROCHLORIDE by Novartis is 12. Approved for parkinson's disease, moderate-to-severe primary restless legs syndrome (rls). First approved in 2010.
Drug data last refreshed 18h ago
12.1 Mechanism of Action Pramipexole is a non-ergot dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D 2 subfamily of dopamine receptors, binding with higher affinity to D 3 than to D 2 or D 4 receptor subtypes. Parkinson's Disease The precise mechanism of…
Worked on PRAMIPEXOLE DIHYDROCHLORIDE at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Bipolar Study of Seroquel XR With Pramipexole Dihydrochloride
Pramipexole Dihydrochloride 0.25 mg Tablets Under Non-Fasting Conditions
Pramipexole Dihydrochloride 0.25 mg Tablets Under Fasting Conditions